LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

0.22 10

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.21

Max

0.22

Põhinäitajad
By Trading Economics
Sissetulek	574K -47M
Müük	3.2M 17M
Aktsiakasum	-0.2
Kasumimarginaal	-275.223
Töötajad	161
EBITDA	1.2M -45M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+2213.04% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-30M 49M
Eelmine avamishind	-9.78
Eelmine sulgemishind	0.22

Uudiste sentiment

By Acuity

80%

20%

316 / 344 Pingereas Healthcare

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. mai 2026, 23:08 UTC

Omandamised, ülevõtmised, äriostud

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29. mai 2026, 23:06 UTC

Omandamised, ülevõtmised, äriostud

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29. mai 2026, 20:53 UTC

Tulu

Oil Declines Lift Stocks to Fresh Records -- WSJ

29. mai 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

29. mai 2026, 20:33 UTC

Market Talk

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29. mai 2026, 20:11 UTC

Tulu

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29. mai 2026, 19:47 UTC

Tulu

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29. mai 2026, 19:36 UTC

Market Talk

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29. mai 2026, 19:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29. mai 2026, 19:34 UTC

Market Talk

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29. mai 2026, 19:22 UTC

Market Talk

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29. mai 2026, 19:05 UTC

Omandamised, ülevõtmised, äriostud

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29. mai 2026, 18:19 UTC

Market Talk

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29. mai 2026, 18:12 UTC

Omandamised, ülevõtmised, äriostud

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29. mai 2026, 18:11 UTC

Market Talk

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29. mai 2026, 18:10 UTC

Market Talk

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29. mai 2026, 17:55 UTC

Tulu

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29. mai 2026, 17:55 UTC

Market Talk

NEAR Protocol Nearly Doubles in May -- Market Talk

29. mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29. mai 2026, 17:00 UTC

Tulu

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29. mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

29. mai 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

29. mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29. mai 2026, 16:02 UTC

Market Talk

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29. mai 2026, 15:55 UTC

Market Talk

Global Equities Roundup: Market Talk

29. mai 2026, 15:55 UTC

Market Talk

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29. mai 2026, 15:50 UTC

Omandamised, ülevõtmised, äriostud

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29. mai 2026, 15:50 UTC

Omandamised, ülevõtmised, äriostud

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29. mai 2026, 15:40 UTC

Market Talk

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29. mai 2026, 15:20 UTC

Market Talk

Canada's Economy Not Looking All That Bright -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

2213.04% tõus

12 kuu keskmine prognoos

Keskmine 5.32 USD 2213.04%

Kõrge 15 USD

Madal 0.28 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

316 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.